Advertisement Covers CROI 2017


Fit for Purpose: Antiretroviral Treatment Optimization

February 28, 2017

Fit for Purpose: Antiretroviral Treatment Optimization

Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones.

These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects.

The ARVs are: dolutegravir (DTG), tenofovir alafenamide (TAF), efavirenz (EFV) 400 mg, and darunavir/ritonavir (DRV/r).

Launched at CROI 2017, this new edition of an annual i-Base publication reviews and updates current and planned research for treatment optimzation studies looking to get increased outcomes from reduced doses in low- and middle-income countries.

Fit for Purpose i-Base -- Feb 2017 (PDF)

Related Stories

Top HIV Researcher Hails a Resurgent Antiretroviral Pipeline

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.